Abstract 763: Implications of resistance patterns with NSCLC targeted agents

Abstract

Abstract Introduction: Tyrosine kinase inhibitors (TKIs) can give regression of NSCLCs with mutations of EGFR, HER2 & BRAF and fusion genes for ALK, ROS1 & RET, but resistance develops in most patients. Methods: We reviewed available clinical data for insights on potential approaches to delay resistance. Results: Target absence is a major cause of intrinsic resistance. Most NSCLCs with target undergo at least some regression although the degree varies between patients due to largely unexplored factors. Many mechanisms of acquired resistance have been defined, including outgrowth of subclones with secondary mutations or alternative pathways, and pharmacological effects & sanctuaries. Available data suggest that resistant cells are present in small numbers in the initial tumor but that their growth is suppressed by the more rapidly growing parent tumor cells until this parent population is itself suppressed by TKI initiation. If TKI is stopped due to progression, there can be tumor flare as the initial parent cell population regrows rapidly. Exponential decay nonlinear regression analysis of patient survival curves suggests that TKI discontinuation at time of progression may partially “synchronize” patient deaths. Initial tumor progression may occur in a single site. Available data indicate that focal treatment (eg, radiation) to that site combined with continuation of initial TKI may give optimal control and reduce tumor flare. Of interest, progression may occur in many sites concurrently. Since there are many potential resistance mechanisms one might expect substantial discordance of resistance mechanisms between these sites, but preliminary data with 2nd line agents (eg, anti-T790M agents in EGFR-mutant patients and 2nd generation anti-ALK agents for acquired resistance to crizotinib) indicate response in most sites if any are sensitive, suggesting that all or most sites have a common resistance mechanism. This raises the possibility that an initial resistant site is seeding other distant tumor sites with resistant cells, in keeping with animal data. The probability of a resistant cell being present in an individual tumor deposit is proportional to the total number of tumor cells in that deposit. If 1 area of resistant tumor can seed other tumor areas with resistant cells, then (particularly in oligometastatic disease) we should consider clinical trials exploring: 1) at initiation of TKI therapy treating as many tumor sites as possible (particularly large tumors) with a modality (eg radiation) that is “indifferent” to the factors giving TKI resistance; 2) treating any progressing lesions as early as possible with intensive focal therapy, if feasible, rather than waiting until symptomatic or rather than treating only with low palliative doses. Conclusion: Extrapolation from available data suggests we should explore trials using multifocal radiation at initiation of TKIs for advanced NSCLC and early, intense treatment of areas of isolated progression. Citation Format: David J. Stewart, Paul Wheatley-Price, Rob MacRae, Jason Pantarotto. Implications of resistance patterns with NSCLC targeted agents. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 763. doi:10.1158/1538-7445.AM2015-763